HR Execs on the Move

HiberCell

www.hibercell.com

 
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.hibercell.com
  • 619 West 54th Street 8th Floor
    New York, NY USA 10019
  • Phone: 212.601.2800

Executives

Name Title Contact Details
Marie Stech
Director Human Resources Profile
Alan Rigby
Co Founder and President Profile

Similar Companies

Parental Therapy Associates

Parental Therapy Associates is a Altamonte Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arsanis Inc

Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.

BioShield Technologies

BioShield Technologies is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Bio-Path Holdings

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.